The OVAL Study: A Randomized Controlled Double-Arm Open-Label Multi-Center Study of VB-111 Combined with Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Ovarian Cancer
  • Age: Between 18 - 100 Years
  • Gender: Female
  • Other Inclusion Criteria:
    1) Histologically confirmed epithelial ovarian cancer and documented disease. 2) Patients must have platinum-resistant disease, defined as a CT confirmed progressive disease completion of a minimum of 4 platinum therapy cycles, or a platinum-refractory disease defined as CT confirmed progression during platinum therapy or up to 90 days from the last administered dose of platinum therapy.

You may not be eligible for this study if the following are true:

  • 1) Non-epithelial tumors (Carcino-sarcomas are excluded). 2) Ovarian tumors with low malignant potential (i.e. borderline tumors), clear cell carcinomas, grade 1 serous tumors or mucinous adenocarcinomas. 3) History of other clinically active malignancy within 5 years of enrollment, except for tumors with a negligible risk for metastasis or death, such as adequately controlled skin basal-cell carcinoma, adequately controlled, nonmetastatic squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast. 4) Previous ovarian cancer treatment with >5 anticancer regimens.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.